1,312 reports of this reaction
2.2% of all HYDRALAZINE HYDROCHLORIDE reports
#11 most reported adverse reaction
HYPERTENSION is the #11 most commonly reported adverse reaction for HYDRALAZINE HYDROCHLORIDE, manufactured by Nivagen Pharmaceuticals, Inc.. There are 1,312 FDA adverse event reports linking HYDRALAZINE HYDROCHLORIDE to HYPERTENSION. This represents approximately 2.2% of all 59,065 adverse event reports for this drug.
Patients taking HYDRALAZINE HYDROCHLORIDE who experience hypertension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERTENSION is a less commonly reported adverse event for HYDRALAZINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to hypertension, the following adverse reactions have been reported for HYDRALAZINE HYDROCHLORIDE:
The following drugs have also been linked to hypertension in FDA adverse event reports:
HYPERTENSION has been reported as an adverse event in 1,312 FDA reports for HYDRALAZINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERTENSION accounts for approximately 2.2% of all adverse event reports for HYDRALAZINE HYDROCHLORIDE, making it a notable side effect.
If you experience hypertension while taking HYDRALAZINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.